前列腺立体定向放疗后泌尿毒性的剂量学线索
本研究基于PROMETHEUS二期试验,分析前列腺癌SBRT boost(19-20 Gy/2次)联合外照射后迟发性泌尿毒性(GU≥2级)与膀胱/尿道剂量的关系。151例中87例有完整剂量数据,19.5%发生迟发GU≥2级毒性;多因素分析显示前列腺尿道长度、尿道PRV体积、膀胱D10cc和D15cc为显著预测因子,建议D10cc<17 Gy、D15cc<15 Gy可能降低风险;既往TURP与GU毒性相关。
要点
- 前列腺SBRT boost联合外照射总体耐受良好,但19.5%患者出现迟发GU≥2级毒性。
- 前列腺尿道长度、尿道PRV体积、膀胱D10cc和D15cc是多因素分析中显著预测GU毒性的因素。
- 建议膀胱D10cc<17 Gy、D15cc<15 Gy可能进一步降低迟发GU毒性风险,既往TURP可能是额外风险因素。
核心结论
- 前列腺SBRT作为虚拟高剂量率boost总体耐受良好,但部分患者出现迟发GU毒性。
- 增加膀胱D10cc<17 Gy和D15cc<15 Gy的约束可能进一步降低迟发GU毒性风险。
- 既往TURP可能是迟发GU毒性的额外风险因素。
研究设计与样本
- PROMETHEUS为二期多中心试验,探索前列腺SBRT boost 19-20 Gy分2次联合分次外照射作为虚拟高剂量率近距离boost。
- 分析87例有完整膀胱和尿道PRV剂量数据的患者,SBRT后≥6个月医生报告的GU毒性。
- 采用单因素和多因素分析,并检查既往TURP与泌尿毒性的关联。
主要发现
- 87例中19.5%在立体定向放疗后>6个月经历GU≥2级毒性。
- 单因素分析中前列腺尿道长度、尿道PRV体积、膀胱D2cc、D5cc、D10cc、D15cc和膀胱V8预测GU毒性(均P<.05)。
- 14例既往TURP患者中6例(43%)发生GU毒性,而无TURP者为15%(P=.015)。
- 多因素分析显示前列腺尿道长度、尿道PRV体积、膀胱D10cc和膀胱D15cc仍为预测GU毒性的显著因素。
关键数值与推荐
- GU毒性分级采用NCI CTCAE 4.0,评估≥2级毒性。
- 膀胱D10cc<17 Gy和D15cc<15 Gy可能进一步降低迟发GU毒性风险。
- SBRT boost剂量为19-20 Gy分2次,联合分次外照射。
临床怎么用
- 在前列腺SBRT计划中可考虑增加膀胱D10cc<17 Gy和D15cc<15 Gy的剂量约束以降低迟发GU毒性。
- 关注前列腺尿道长度和尿道PRV体积等剂量学参数,优化尿道保护。
- 对既往接受TURP的患者应警惕迟发GU毒性风险。
局限性
- 仅87例有完整剂量数据纳入分析,样本量有限。
- 为单因素和多因素回顾性剂量-毒性关联分析,需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Delayed genitourinary (GU) toxicity is reported following definitive stereotactic body radiation therapy (SBRT) for prostate cancer in 15% to 30% of patients. The purpose of this study is to investigate whether there is a relationship between radiation dose to the bladder and urethra and GU toxicity grade ≥ 2 (National Cancer Institute Common Terminology Criteria for Adverse Events 4.0) in patients treated with SBRT. METHODS AND MATERIALS: PROstate Multicenter External beam radioTHErapy Using Stereotactic boost was a phase 2 multicenter trial exploring an SBRT boost of 19 to 20 Gy in 2 fractions to the prostate combined with fractionated external beam radiation therapy as a virtual high-dose-rate brachytherapy boost for patients with prostate cancer. Several bladder and urethral constraints were mandated prospectively. Bladder and the urethral planning organ at risk volume (PRV) dosimetry was correlated with physician-reported GU toxicity for patients ≥ 6 months following SBRT. An association between prior transurethral resection of the prostate (TURP) and urinary toxicity was also examined. Univariant and multivariate analyses were performed. RESULTS: Of the 151 patients, 87 had complete dosimetric data, and these patients were included in this analysis. In this cohort, 19.5% experienced grade ≥ 2 GU toxicity more than 6 months after stereotactic radiation therapy. On univariate analysis, prostatic urethral length, urethral PRV volume, bladder D2 cc, D5 cc, D10 cc, D15 cc, and bladder V8 were predictive of GU toxicity (all P < .05). In the 14 patients who had prior TURP, 6 (43%) experienced GU toxicity compared with 15% for those without prior TURP (P = .015). Multivariate analysis showed that prostatic urethral length, urethral PRV volume, bladder 10 cc, and bladder 15 cc remained statistically significant factors predicting GU toxicity. CONCLUSIONS: Prostate SBRT delivered as a virtual high-dose-rate boost is well tolerated overall. However, delayed GU toxicity is experienced by a significant minority of patients. Additional bladder constraints including D10 cc < 17 Gy and D15 cc < 15 Gy may further reduce the risk of delayed GU toxicity. Prior TURP may be a plausible additional risk factor.
引用
- Cardoso M, Richardson M, Chlap P, et al. Dosimetric Clues to Addressing Urinary Toxicity Following Stereotactic Prostate Radiation Therapy. Adv Radiat Oncol. 2025. PMID: 40747327. doi:10.1016/j.adro.2025.101850
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。